MedTrace Logo

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma

NCT05845502 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-01-29

No results posted yet for this study

Summary

This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ003 in the treatment of advanced hepatocellular carcinoma.

Conditions

Interventions

BIOLOGICAL

SZ003 CAR-NK

Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.

Sponsors & Collaborators

  • Guangdong ProCapZoom Biosciences Co., Ltd.

    collaborator INDUSTRY

  • Shantou University Medical College

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05845502 on ClinicalTrials.gov